Tempest Therapeutics Q4 EPS $(0.62) Beats $(3.52) Estimate

Tempest Therapeutics (NASDAQ: TPST) reported Q4 earnings with a loss of $(0.62) per share, surpassing the analyst consensus estimate of $(3.52) by 82.39%. This represents an 87.77% improvement compared to losses of $(5.07) per share in the same quarter last year.